These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 19636012)

  • 1. Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium.
    Milowsky MI; Nanus DM; Maluf FC; Mironov S; Shi W; Iasonos A; Riches J; Regazzi A; Bajorin DF
    J Clin Oncol; 2009 Sep; 27(25):4062-7. PubMed ID: 19636012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract.
    Dodd PM; McCaffrey JA; Hilton S; Mazumdar M; Herr H; Kelly WK; Icasiano E; Boyle MG; Bajorin DF
    J Clin Oncol; 2000 Feb; 18(4):840-6. PubMed ID: 10673526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results.
    Siefker-Radtke AO; Dinney CP; Shen Y; Williams DL; Kamat AM; Grossman HB; Millikan RE
    Cancer; 2013 Feb; 119(3):540-7. PubMed ID: 22914978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy.
    Sternberg CN; Calabrò F; Pizzocaro G; Marini L; Schnetzer S; Sella A
    Cancer; 2001 Dec; 92(12):2993-8. PubMed ID: 11753976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy with gemcitabine, paclitaxel, and cisplatin in the treatment of patients with advanced transitional cell carcinoma of the urothelium.
    Ecke TH; Bartel P; Koch S; Ruttloff J; Theissig F
    Oncol Rep; 2006 Dec; 16(6):1381-8. PubMed ID: 17089065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current and future perspectives in advanced bladder cancer: is there a new standard?
    von der Maase H
    Semin Oncol; 2002 Feb; 29(1 Suppl 3):3-14. PubMed ID: 11894002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Palliative chemotherapy with gemcitabine, paclitaxel, and cisplatin as first-line treatment following gemcitabine monotherapy for patients with transitional cell carcinoma of the urothelium.
    Ecke TH; Gerullis H; Bartel P; Koch S; Ruttloff J
    Minerva Urol Nefrol; 2009 Mar; 61(1):1-8. PubMed ID: 19417721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules.
    Bajorin DF; McCaffrey JA; Dodd PM; Hilton S; Mazumdar M; Kelly WK; Herr H; Scher HI; Icasiano E; Higgins G
    Cancer; 2000 Apr; 88(7):1671-8. PubMed ID: 10738226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: a phase II trial.
    Bajorin DF; McCaffrey JA; Hilton S; Mazumdar M; Kelly WK; Scher HI; Spicer J; Herr H; Higgins G
    J Clin Oncol; 1998 Aug; 16(8):2722-7. PubMed ID: 9704723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group.
    Bellmunt J; Guillem V; Paz-Ares L; González-Larriba JL; Carles J; Batiste-Alentorn E; Sáenz A; López-Brea M; Font A; Nogué M; Bastús R; Climent MA; de la Cruz JJ; Albanell J; Banús JM; Gallardo E; Diaz-Rubio E; Cortés-Funes H; Baselga J
    J Clin Oncol; 2000 Sep; 18(18):3247-55. PubMed ID: 10986057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomised, open-label, phase II trial of paclitaxel, gemcitabine and cisplatin versus gemcitabine and cisplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium.
    Lorusso V; Crucitta E; Silvestris N; Rosati G; Manzione L; De Lena M; Palmeri S; Gebbia V; Mancarella S; Sobrero A; Pezzella G; Comella P; Mangiameli A; Muci D;
    Oncol Rep; 2005 Feb; 13(2):283-7. PubMed ID: 15643512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial.
    Dogliotti L; Cartenì G; Siena S; Bertetto O; Martoni A; Bono A; Amadori D; Onat H; Marini L
    Eur Urol; 2007 Jul; 52(1):134-41. PubMed ID: 17207911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer.
    Roberts JT; von der Maase H; Sengeløv L; Conte PF; Dogliotti L; Oliver T; Moore MJ; Zimmermann A; Arning M
    Ann Oncol; 2006 May; 17 Suppl 5():v118-22. PubMed ID: 16807438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of gemcitabine and paclitaxel is a favorable option for patients with advanced or metastatic urothelial carcinoma previously treated with cisplatin-based chemotherapy.
    Ikeda M; Matsumoto K; Tabata K; Minamida S; Fujita T; Satoh T; Iwamura M; Baba S
    Jpn J Clin Oncol; 2011 Oct; 41(10):1214-20. PubMed ID: 21903707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study.
    Li J; Juliar B; Yiannoutsos C; Ansari R; Fox E; Fisch MJ; Einhorn LH; Sweeney CJ
    J Clin Oncol; 2005 Feb; 23(6):1185-91. PubMed ID: 15718315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial.
    Pectasides D; Glotsos J; Bountouroglou N; Kouloubinis A; Mitakidis N; Karvounis N; Ziras N; Athanassiou A
    Ann Oncol; 2002 Feb; 13(2):243-50. PubMed ID: 11886001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.
    von der Maase H; Hansen SW; Roberts JT; Dogliotti L; Oliver T; Moore MJ; Bodrogi I; Albers P; Knuth A; Lippert CM; Kerbrat P; Sanchez Rovira P; Wersall P; Cleall SP; Roychowdhury DF; Tomlin I; Visseren-Grul CM; Conte PF
    J Clin Oncol; 2000 Sep; 18(17):3068-77. PubMed ID: 11001674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network.
    Meluch AA; Greco FA; Burris HA; O'Rourke T; Ortega G; Steis RG; Morrissey LH; Johnson V; Hainsworth JD
    J Clin Oncol; 2001 Jun; 19(12):3018-24. PubMed ID: 11408496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methotrexate-paclitaxel-epirubicin-carboplatin as second-line chemotherapy in patients with metastatic transitional cell carcinoma of the bladder pretreated with cisplatin-gemcitabine: a phase II study.
    Halim A; Abotouk N
    Asia Pac J Clin Oncol; 2013 Mar; 9(1):60-5. PubMed ID: 22897883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine and paclitaxel chemotherapy for advanced urothelial carcinoma in patients who have received prior cisplatin-based chemotherapy.
    Kanai K; Kikuchi E; Ohigashi T; Miyajima A; Nakagawa K; Nakashima J; Oya M
    Int J Clin Oncol; 2008 Dec; 13(6):510-4. PubMed ID: 19093178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.